

Vincent Ribrag

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4895356/publications.pdf>

Version: 2024-02-01

52
papers

4,331
citations

218381

26
h-index

189595

50
g-index

55
all docs

55
docs citations

55
times ranked

5566
citing authors

#	ARTICLE	IF	CITATIONS
1	Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure. <i>Journal of Clinical Oncology</i> , 2016, 34, 3733-3739.	0.8	586
2	Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study. <i>Lancet Oncology</i> , The, 2018, 19, 649-659.	5.1	450
3	Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. <i>Lancet</i> , The, 2016, 388, 565-575.	6.3	328
4	Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2017, 377, 1250-1260.	13.9	313
5	Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1433-1442.	5.1	306
6	Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma. <i>Blood</i> , 2017, 130, 267-270.	0.6	255
7	Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087. <i>Blood</i> , 2019, 134, 1144-1153.	0.6	255
8	CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte. <i>Blood</i> , 2013, 121, 48-53.	0.6	243
9	Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 3291-3299.	0.8	195
10	Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial. <i>Lancet Haematology</i> , the, 2019, 6, e459-e469.	2.2	174
11	Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial. <i>Lancet</i> , The, 2016, 387, 2402-2411.	6.3	157
12	High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma. <i>Blood</i> , 2015, 126, 604-611.	0.6	130
13	Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hematologic and Solid Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 7331-7339.	3.2	110
14	Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II study. <i>Haematologica</i> , 2017, 102, 903-909.	1.7	64
15	Phase 1b trial of pembrolizumab monotherapy for relapsed/refractory multiple myeloma: <sc>KEYNOTE</sc>. <i>British Journal of Haematology</i> , 2019, 186, e41-e44.	1.2	59
16	Alternating Courses of 3x CHOP and 3x DHAP Plus Rituximab Followed by a High Dose ARA-C Containing Myeloablative Regimen and Autologous Stem Cell Transplantation (ASCT) Increases Overall Survival When Compared to 6 Courses of CHOP Plus Rituximab Followed by Myeloablative Radiochemotherapy and ASCT in Mantle Cell Lymphoma: Final Analysis of the MCL Younger Trial of the European Mantle Cell Lymphoma Network (MCL net). <i>Blood</i> , 2012, 120, 151-151.	0.6	52
17	Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier. <i>Blood</i> , 2020, 135, 996-1007.	0.6	49
18	A LYSA Phase Ib Study of Tazemetostat (EPZ-6438) plus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) with Poor Prognosis Features. <i>Clinical Cancer Research</i> , 2020, 26, 3145-3153.	3.2	48

#	ARTICLE	IF	CITATIONS
19	Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA. <i>Blood</i> , 2021, 137, 2307-2320.	0.6	48
20	Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies. <i>Clinical Cancer Research</i> , 2017, 23, 6411-6420.	3.2	43
21	Droplet Digital PCR Quantification of Mantle Cell Lymphoma Follow-up Samples From Four Prospective Trials of the European MCL Network. <i>HemaSphere</i> , 2020, 4, e347.	1.2	36
22	Expression of the Immune Checkpoint Regulators LAG-3 and TIM-3 in Classical Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 257-266.e3.	0.2	35
23	Phase 1 study of the oral histone deacetylase inhibitor abexinostat in patients with Hodgkin lymphoma, non-Hodgkin lymphoma, or chronic lymphocytic leukaemia. <i>Investigational New Drugs</i> , 2015, 33, 423-431.	1.2	33
24	Concurrent Etoposide, Steroid, High-dose Ara-C and Platinum chemotherapy with radiation therapy in localised extranodal natural killer (NK)/T-cell lymphoma, nasal type. <i>European Journal of Cancer</i> , 2015, 51, 2386-2395.	1.3	32
25	Kinetics and nadir of responses to immune checkpoint blockade by anti-PD1 in patients with classical Hodgkin lymphoma. <i>European Journal of Cancer</i> , 2018, 91, 136-144.	1.3	32
26	Pembrolizumab in relapsed or refractory Richter syndrome. <i>British Journal of Haematology</i> , 2020, 190, e117-e120.	1.2	29
27	Burkitt and Burkitt-Like Lymphomas: a Systematic Review. <i>Current Oncology Reports</i> , 2020, 22, 33.	1.8	28
28	Poor predictive value of positive interim FDG-PET/CT in primary mediastinal large B-cell lymphoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 2018-2024.	3.3	27
29	Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study. <i>Lancet Haematology</i> , 2020, 7, e649-e659.	2.2	24
30	Treatment for patients with relapsed/refractory mantle cell lymphoma: European-based recommendations. <i>Leukemia and Lymphoma</i> , 2018, 59, 1814-1828.	0.6	23
31	Screening a Broad Range of Solid and Haematological Tumour Types for CD70 Expression Using a Uniform IHC Methodology as Potential Patient Stratification Method. <i>Cancers</i> , 2019, 11, 1611.	1.7	23
32	Can Next-Generation PI3K Inhibitors Unlock the Full Potential of the Class in Patients With B-Cell Lymphoma?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 8-20.e3.	0.2	23
33	A Phase 1b Study to Evaluate the Safety and Efficacy of Durvalumab in Combination With Tremelimumab or Danvatirsén in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 309-317.e3.	0.2	17
34	Primary mediastinal large B-cell lymphomas treated with dose-intensified CHOP alone or CHOP combined with radiotherapy. <i>Leukemia and Lymphoma</i> , 2008, 49, 1510-1515.	0.6	16
35	Treatment of Younger Patients With Mantle Cell Lymphoma. <i>Seminars in Hematology</i> , 2011, 48, 194-207.	1.8	10
36	Pembrolizumab for myelodysplastic syndromes after failure of hypomethylating agents in the phase 1b KEYNOTE-013 study. <i>Leukemia and Lymphoma</i> , 2022, 63, 1660-1668.	0.6	10

#	ARTICLE	IF	CITATIONS
37	Pirtobrutinib shows evidence to inaugurate a third generation of BTK inhibitors. <i>Lancet, The</i> , 2021, 397, 855-857.	6.3	9
38	Repeated courses of low-dose 2-2 Gy radiation therapy in patients with indolent B-cell non-Hodgkin lymphomas. <i>Cancer Medicine</i> , 2020, 9, 3725-3732.	1.3	8
39	Novel agents for mantle cell lymphoma: molecular rational and clinical data. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 555-566.	1.9	7
40	Deep-Learning Assessed Muscular Hypodensity Independently Predicts Mortality in DLBCL Patients Younger Than 60 Years. <i>Cancers</i> , 2021, 13, 4503.	1.7	7
41	Phase Ib study of avadomide (CC-122) in combination with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma. <i>EJHaem</i> , 2022, 3, 394-405.	0.4	7
42	Outcomes of Transplant-Eligible Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma After Second-Line Salvage Chemotherapy: The Gustave Roussy Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e373-e380.	0.2	6
43	Oxaliplatin before autologous transplantation in combination with high-dose cytarabine and rituximab provides longer disease control than cisplatin or carboplatin in patients with mantle-cell lymphoma: results from the LyMA prospective trial. <i>Bone Marrow Transplantation</i> , 2021, 56, 1700-1709.	1.3	6
44	Phase Ib study of combinations of avadomide (CC-122), CC-223, CC-292, and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma. <i>EJHaem</i> , 2022, 3, 139-153.	0.4	4
45	Pembrolizumab in the treatment of refractory primary mediastinal large B-cell lymphoma: safety and efficacy. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 941-956.	1.1	3
46	Novel targeted therapeutics for mantle cell lymphoma – What’s on the horizon?. <i>Expert Review of Hematology</i> , 2016, 9, 271-281.	1.0	2
47	Clinical significance of the loss of CD20 antigen on tumor cells in patients with relapsed or refractory follicular lymphoma. , 2021, 4, 710-718.		2
48	Quality of life of survivors 1 year after the diagnosis of diffuse large B-cell lymphoma: a LYSA study. <i>Annals of Hematology</i> , 2022, 101, 317-332.	0.8	2
49	Attenuated cytarabine, etoposide, dexamethasone plus rituximab (R-MINIC-YVE) regimen for patients with relapsed or refractory B-cell non-Hodgkin lymphoma not eligible for intensive chemotherapy. <i>European Journal of Haematology</i> , 2021, 106, 574-583.	1.1	1
50	Molecular Profiling Feasibility on Cell-Free Tumoral DNA in Relapse/Refractory (R/R) Multiple Myeloma (MM) Patients Screened for Phase I Trials. <i>Blood</i> , 2021, 138, 3763-3763.	0.6	1
51	Cell-free DNA sequencing as a potential screening tool for phase I targeted treatment in refractory/relapse diffuse large B-cell lymphoma. <i>Haematologica</i> , 2022, 107, 1928-1932.	1.7	1
52	Relapsed and refractory classical Hodgkin lymphoma: could virotherapy help solve the equation?. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 3502-3510.	1.4	0